- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00112554
Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia
A Phase III Randomized of Cloretazine™ (VNP40101M) and Cytosine Arabinoside (AraC) in Patients With Acute Myeloid Leukemia in First Relapse
RATIONALE: Drugs used in chemotherapy, such as cytarabine and VNP40101M, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.
PURPOSE: This randomized phase III trial is studying cytarabine and VNP40101M to see how well they work compared to cytarabine alone in treating patients with relapsed acute myeloid leukemia.
연구 개요
상세 설명
OBJECTIVES:
Primary
- Compare the complete response (CR) and CR (with platelet count < 100,000/mm^3 but ≥ 20,000/mm^3 [transfusion independent for ≥ 7 consecutive days]) (CRp) rates in patients with acute myeloid leukemia in first relapse treated with cytarabine with vs without VNP40101M.
Secondary
- Compare time to progression in patients treated with these regimens.
- Compare duration of response in patients treated with these regimens.
- Compare the survival of patients treated with these regimens.
- Compare the toxicity of these regimens in these patients.
OUTLINE: This is a randomized, double-blind, placebo-controlled, parallel group, multicenter study. Patients are stratified according to age (< 60 years vs ≥ 60 years) and duration of first complete response (CR) or CR (with platelet count < 100,000/mm³ but ≥ 20,000/mm³ [transfusion independent for ≥ 7 consecutive days]) (CRp) (< 12 months vs ≥ 12 months).
Induction therapy: Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive cytarabine IV continuously on days 1-3 and VNP40101M IV over 30-60 minutes on day 2 (at least 12 hours after the start of cytarabine).
- Arm II: Patients receive cytarabine as in arm I and placebo IV over 30-60 minutes on day 2 (at least 12 hours after the start of cytarabine).
In both arms, patients demonstrating at least 20% reduction of blasts in bone marrow (based on total cellularity and percent blasts) after course 1 may receive 1 additional course of induction therapy between days 35-60 in the absence of disease progression or unacceptable toxicity. Patients achieving CR or CRp after 1 or 2 courses of induction therapy proceed to consolidation therapy.
- Consolidation therapy: Beginning 6 weeks after initial documentation of CR or CRp, patients receive 1 course of consolidation therapy, as per induction therapy, according to their randomized treatment arm. These patients may then proceed to other consolidation, maintenance, and/or intensification therapy (including stem cell transplantation) off study at the discretion of the physician.
After completion of study treatment, patients are followed monthly for 6 months, every 2 months for 6 months, and then every 3 months for 2 years.
PROJECTED ACCRUAL: A total of 420 patients (280 in arm I and 140 in arm II) will be accrued for this study within 24-30 months.
연구 유형
등록 (예상)
단계
- 3단계
연락처 및 위치
연구 장소
-
-
-
Athens, 그리스, 10676
- Evaggelismos Hospital
-
Rio Patras, 그리스, GR-26500
- University of Patras Medical School
-
-
-
-
-
Groningen, 네덜란드, 9713 GZ
- University Medical Center Groningen
-
-
-
-
-
Berlin, 독일, D-12200
- Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin
-
Cologne, 독일, D-50924
- Medizinische Universitaetsklinik I at the University of Cologne
-
Frankfurt, 독일, D-60596
- Universitaetsfrauenklinik Frankfurt
-
Heidelberg, 독일, D-69115
- UniversitatsKlinikum Heidelberg
-
Muenster, 독일, D-48149
- Medizinische Klinik und Poliklinik A - Universitaetsklinikum Muenster
-
Munich, 독일, D-81377
- Klinikum der Universitaet Muenchen - Grosshadern Campus
-
Wurzburg, 독일, D-97070
- University Würzburg
-
-
-
-
California
-
Los Angeles, California, 미국, 90095-1781
- Jonsson Comprehensive Cancer Center at UCLA
-
Los Angeles, California, 미국, 90089-9181
- USC/Norris Comprehensive Cancer Center and Hospital
-
Orange, California, 미국, 92868
- Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center
-
San Francisco, California, 미국, 94115
- UCSF Comprehensive Cancer Center
-
-
Connecticut
-
Hartford, Connecticut, 미국, 06105
- Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
-
-
Florida
-
Miami, Florida, 미국, 33136
- University of Miami Sylvester Comprehensive Cancer Center
-
Tampa, Florida, 미국, 33612
- Veterans Affairs Medical Center - Tampa (Haley)
-
-
Illinois
-
Chicago, Illinois, 미국, 60637-1470
- University of Chicago Cancer Research Center
-
Chicago, Illinois, 미국, 60611-3013
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46260
- American Health Network - North Meridian
-
-
Maryland
-
Baltimore, Maryland, 미국, 21201
- Greenebaum Cancer Center at University of Maryland Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02115
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
-
-
Nevada
-
Las Vegas, Nevada, 미국, 89135
- Nevada Cancer Institute
-
-
New Mexico
-
Albuquerque, New Mexico, 미국, 87106
- New Mexico Cancer Care Alliance
-
-
New York
-
Buffalo, New York, 미국, 14263-0001
- Roswell Park Cancer Institute
-
Valhalla, New York, 미국, 10595
- New York Medical College
-
-
North Carolina
-
Durham, North Carolina, 미국, 27710
- Duke Comprehensive Cancer Center
-
Greenville, North Carolina, 미국, 27858
- Brody School of Medicine at East Carolina University
-
-
Ohio
-
Columbus, Ohio, 미국, 43214-3998
- Riverside Methodist Hospital Cancer Care
-
-
Pennsylvania
-
Hershey, Pennsylvania, 미국, 17033-0850
- Penn State Cancer Institute at Milton S. Hershey Medical Center
-
Pittsburgh, Pennsylvania, 미국, 15224
- Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
-
-
South Carolina
-
Charleston, South Carolina, 미국, 29425
- Hollings Cancer Center at Medical University of South Carolina
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37232-6838
- Vanderbilt-Ingram Cancer Center
-
-
Texas
-
Houston, Texas, 미국, 77030-4009
- M.D. Anderson Cancer Center at University of Texas
-
-
-
-
-
Brussels, 벨기에, 1200
- Cliniques universitaires Saint-Luc
-
Leuven, 벨기에, B-3000
- U.Z. Gasthuisberg
-
Montigny-le-Tilleul, 벨기에, 6110
- CHU Charleroi - Site Vesale
-
-
-
-
-
Belgrade, 세르비아, 11000
- Clinical Centre of Serbia
-
Nis, 세르비아, 18000
- Clinical Centre Nis
-
Novi Sad, 세르비아, 21000
- Clinic Centre Novi Sad
-
-
-
-
England
-
Birmingham, England, 영국, B9 5SS
- Birmingham Heartlands Hospital
-
Cambridge, England, 영국, CB2 2QQ
- Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust
-
Leicester, England, 영국, LE1 5WW
- Leicester Royal Infirmary
-
London, England, 영국, SE5 9RS
- King's College Hospital
-
Manchester, England, 영국, M13 9WL
- Manchester Royal Infirmary
-
-
Wales
-
Cardiff, Wales, 영국, CF14 4XW
- University Hospital of Wales
-
-
-
-
British Columbia
-
Vancouver, British Columbia, 캐나다, V5Z 4E3
- Vancouver Hospital and Health Science Center
-
-
New Brunswick
-
Saint John, New Brunswick, 캐나다, E2L 4L2
- Saint John Regional Hospital
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, 캐나다, A1B 3V6
- Memorial University of Newfoundland
-
-
Nova Scotia
-
Halifax, Nova Scotia, 캐나다, B3H 1V7
- Capital District Health Authority Center for Clinical Research
-
-
Ontario
-
Ottawa, Ontario, 캐나다, K1H 8L6
- Ottawa Hospital Regional Cancer Centre - General Campus
-
Toronto, Ontario, 캐나다, M5G 2M9
- Princess Margaret Hospital
-
-
-
-
-
Gdansk, 폴란드, 80-211
- Medical University of Gdansk
-
Lodz, 폴란드, 90-419
- Medical University of Lodz
-
Lublin, 폴란드, 20-954
- Centrum Onkologii Ziemi Lubelskiez
-
Warsaw, 폴란드, 00-957
- Institute of Haematology and Blood Transfusion
-
Warsaw, 폴란드, 00-909
- Wojskowy Instytut Medyczny
-
-
-
-
-
Besancon, 프랑스, 25030
- Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz
-
Lyon, 프랑스, 69437
- Hôpital Edouard Herriot
-
Marseille, 프랑스, 13273
- Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes
-
Nantes, 프랑스, 44093
- CHR Hotel Dieu
-
Pessac, 프랑스, 33604
- Hôpital Haut Leveque
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
DISEASE CHARACTERISTICS:
Histologically confirmed acute myeloid leukemia (AML)
- Any WHO classification, excluding acute promyelocytic leukemia
- At least 10% blasts by bone marrow aspirate and/or biopsy
In first relapse after achieving a first complete response (CR) OR CR (with platelet count < 100,000/mm³ but ≥ 20,000/mm³ [transfusion independent for ≥ 7 consecutive days]) (CRp) that lasted ≥ 3 months but ≤ 24 months after completion of the initial induction regimen
- Relapse confirmed by recurrence of blasts in peripheral blood, bone marrow histopathology, and/or histologically confirmed CNS or extramedullary disease
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- ECOG 0-2
Life expectancy
- Not specified
Hematopoietic
- See Disease Characteristics
Hepatic
- Bilirubin ≤ 1.5 times upper limit of normal (ULN)
- AST ≤ 3 times ULN
- Chronic hepatitis allowed
Renal
- Creatinine ≤ 2.0 mg/dL
Cardiovascular
- No myocardial infarction within the past 3 months
- No uncontrolled arrhythmias
- No uncontrolled congestive heart failure
Pulmonary
- No severe chronic obstructive pulmonary disease
- No requirement for supplemental oxygen at rest
Immunologic
No uncontrolled active infection
- Infections that are controlled and under active treatment with antibiotics allowed
- No evidence of invasive fungal infection by blood or tissue cultures
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 3 months after completion of study treatment
- No clinical evidence of another active malignancy by tumor marker, pathology, or radiologic studies
- No other severe medical condition that would preclude study treatment
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- At least 12 hours since prior hydroxyurea
Endocrine therapy
- Not specified
Radiotherapy
- Not specified
Surgery
- Not specified
Other
- No prior treatment while in first relapse except hydroxyurea
- No other concurrent standard or investigational treatment for AML
- No concurrent disulfiram (Antabuse®)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Induction therapy arm I
Patients receive cytarabine IV continuously on days 1-3 and VNP40101M IV over 30-60 minutes on day 2 (at least 12 hours after the start of cytarabine).
|
주어진 IV
Given IV
|
활성 비교기: Induction therapy arm II
Patients receive cytarabine as in arm I and placebo IV over 30-60 minutes on day 2 (at least 12 hours after the start of cytarabine).
|
주어진 IV
주어진 IV
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
---|
전체 응답률
|
2차 결과 측정
결과 측정 |
---|
독성
|
응답 기간
|
전반적인 반응
|
종양 진행 시간
|
공동 작업자 및 조사자
수사관
- Bonny L. Johnson, RN, MSN, Vion Pharmaceuticals
간행물 및 유용한 링크
일반 간행물
- Giles F, Vey N, DeAngelo D, Seiter K, Stock W, Stuart R, Boskovic D, Pigneux A, Tallman M, Brandwein J, Kell J, Robak T, Staib P, Thomas X, Cahill A, Albitar M, O'Brien S. Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse. Blood. 2009 Nov 5;114(19):4027-33. doi: 10.1182/blood-2009-06-229351. Epub 2009 Aug 26.
- Giles FJ, Stock W, Vey N, et al.: A double blind placebo-controlled randomized phase III study of high dose continuous infusion cytosine arabinoside (araC) with or without cloretazine in patients with first relapse of acute myeloid leukemia (AML). [Abstract] Blood 108 (11): A-1970, 2006.
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
- 11q23(MLL) 이상이 있는 성인 급성 골수성 백혈병
- inv(16)(p13;q22)가 있는 성인 급성 골수성 백혈병
- t(16;16)(p13;q22)가 있는 성인 급성 골수성 백혈병
- t(8;21)(q22;q22)가 있는 성인 급성 골수성 백혈병
- 재발성 성인 급성 골수성 백혈병
- 성인 급성 거핵모구성 백혈병(M7)
- 성인 급성 최소 분화 골수성 백혈병(M0)
- 성인 급성 단구성 백혈병(M5a)
- 성인 급성 단핵구 백혈병(M5b)
- 성숙한 성인 급성 골수성 백혈병(M2)
- 성숙하지 않은 성인 급성 골수성 백혈병(M1)
- 성인 급성 골수단구성 백혈병(M4)
- 성인 급성 호염기성 백혈병
- 성인급성호산구성백혈병
- 성인 적백혈병(M6a)
- 성인 순수 적혈구성 백혈병(M6b)
추가 관련 MeSH 약관
기타 연구 ID 번호
- CDR0000430677
- VION-CLI-037
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
시타라빈에 대한 임상 시험
-
Assistance Publique - Hôpitaux de ParisFrench Innovative Leukemia Organisation; Acute Leukemia French Association완전한
-
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co....모병
-
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co....알려지지 않은
-
University of Maryland, BaltimoreHematologics, Inc모병
-
University Hospital MuensterCelgene Corporation; Amgen완전한
-
The First Affiliated Hospital of Soochow University모병
-
The First Affiliated Hospital with Nanjing Medical...Huai'an First People's Hospital; Yancheng First People's Hospital모병